Naples Global Advisors LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Naples Global Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,759 shares of the company’s stock after purchasing an additional 689 shares during the quarter. Naples Global Advisors LLC’s holdings in Johnson & Johnson were worth $7,754,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Lantz Financial LLC grew its stake in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter worth $453,000. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $949,000. Horan Securities Inc. grew its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after buying an additional 90 shares during the last quarter. Finally, Strategic Financial Concepts LLC lifted its holdings in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $153.39 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company’s 50-day moving average price is $153.81 and its two-hundred day moving average price is $153.67. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market cap of $369.07 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.